scholarly journals Bullous Pemphigoid Associated with Adalimumab Therapy in a Patient with Ulcerative Colitis

2018 ◽  
Vol 10 (2) ◽  
pp. 145-148 ◽  
Author(s):  
Sebastian Hoffmann ◽  
Mark Berneburg ◽  
Stephan Schreml
Keyword(s):  
Ulcerative Colitis ◽  
Autoimmune Disease ◽  
Elderly Patients ◽  
Bullous Pemphigoid ◽  
Lupus Erythematosus ◽  
Systemic Therapy ◽  
Rare Case ◽  
Case Reports ◽  
Adalimumab Therapy ◽  
Tnf Inhibition

Bullous pemphigoid (BP) is a blistering autoimmune disease mainly observed in elderly patients. Several triggers are known for this autoimmune disease and some drugs are known to be a cause of BP. However, there are only few case reports on the induction of BP under adalimumab therapy. Other autoimmune diseases, such as lupus erythematosus, are also known to occur under TNF inhibition. Here, we report on an 81-year-old patient who received adalimumab for ulcerative colitis and subsequently developed BP. Other causes of BP (tumors, other drugs, viral or toxoplasma infections) were excluded. We initiated a topical and systemic therapy (prednisolone 1 mg/kg/day) and stopped the adalimumab injections. The patient’s symptoms resolved quickly and we were able to taper corticosteroid therapy. This rare case highlights the importance to monitor for autoimmune events during TNF inhibition.

scholarly journals Analytical Review: Leukemia or Lymphoma Occurring Subsequent to an Autoimmune Disease

Blood ◽  
1967 ◽  
Vol 29 (1) ◽  
pp. 144-153 ◽  
Author(s):  
ARTHUR OLEINICK
Keyword(s):  
Rheumatoid Arthritis ◽  
Autoimmune Disease ◽  
Lupus Erythematosus ◽  
Case Reports ◽  
Systemic Lupus ◽  
Mortality Experience ◽  
Direct Support ◽  
In Series ◽  
Analytical Review ◽  
Alternative Approaches

Abstract The hypothesis of undue susceptibility to leukemia or lymphoma in individuals with autoimmune disease is evaluated by an analysis of case reports and an analysis of the mortality experience of series of patients with systemic lupus erythematosus or rheumatoid arthritis. No direct support for the hypothesis is found. The difficulty in accumulating a sufficient number of person years at risk in series of individuals with autoimmune disease is noted and alternative approaches to validating this hypothesis are discussed.

Systemic lupus erythematosus reactivation after chemoimmunotherapy in preexisting autoimmune disease

2022 ◽  
pp. 030089162110675
Author(s):  
Andrea Spagnoletti ◽  
Marco Platania ◽  
Marta Brambilla ◽  
Mario Occhipinti ◽  
Luca Canziani ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Autoimmune Disease ◽  
Lupus Erythematosus ◽  
Checkpoint Inhibitors ◽  
Case Reports ◽  
Severe Toxicity ◽  
Systemic Lupus ◽  
Life Threatening ◽  
Few Data ◽  
Analyze Data

The use of immune checkpoint inhibitors (ICIs) offers new possibilities in modern treatment of many types of cancers. Few data regarding safety and efficacy of ICIs are available, and are mainly from retrospective studies and case reports rather than from clinical trials, in the context of preexisting autoimmune disease, mainly due to the risk of severe toxicity. We present an unexpected life-threatening reactivation of systemic lupus erythematosus after one dose of chemo-immunotherapy with pembrolizumab for oligometastatic non-small-cell lung cancer. We analyze data coming from the published literature in this setting and discuss the risk–benefit balance of immunotherapy in patients with preexisting severe autoimmune disease.

Bullous Pemphigoid Associated with Acquired Hemophilia A: A Rare Association of Autoimmune Disease

2014 ◽  
Vol 18 (2) ◽  
pp. 123-126 ◽  
Author(s):  
Mohammed I. AlJasser ◽  
Chris Sladden ◽  
Richard I. Crawford ◽  
Sheila Au
Keyword(s):  
Autoimmune Disease ◽  
Factor Viii ◽  
Bullous Pemphigoid ◽  
Lupus Erythematosus ◽  
Pemphigus Vulgaris ◽  
Factor Viii Inhibitor ◽  
Acquired Hemophilia ◽  
Inhibitor Level ◽  
Viii Level ◽  
Skin Biopsies

Background: Acquired hemophilia (AH) is a rare autoimmune disease with an annual incidence of one per million and has a mortality rate of up to 22%. It is caused by the development of autoantibodies against factor VIII. Approximately half of the reported cases are associated with autoimmune disorders, pregnancy, malignancies, and adverse drug reactions. Autoimmune diseases are the most frequently associated disorders and include rheumatoid arthritis, systemic lupus erythematosus, cryoglobulinemia, pemphigus vulgaris, and bullous pemphigoid. There are a few reports of acquired hemophilia and bullous pemphigoid in the literature. Method: We report a 73-year-old male who presented with cutaneous blistering, upper gastrointestinal bleeding, and hemoptysis. He later developed right flank pain secondary to a retroperitoneal hematoma. He had a prolonged partial thromboplastin time, a low factor VIII level, and a high factor VIII inhibitor level, all consistent with acquired hemophilia. Skin biopsies were diagnostic for bullous pemphigoid. Results: He was treated successfully with prednisone, cyclophosphamide, rituximab, and intravenous immunoglobulin.

Linezolid Induced Skin Reactions in a Multi Drug Resistant Infective Endocarditis Patient: A Rare Case

2020 ◽  
Vol 15 (3) ◽  
pp. 222-226 ◽  
Author(s):  
Asha K. Rajan ◽  
Ananth Kashyap ◽  
Manik Chhabra ◽  
Muhammed Rashid
Keyword(s):  
Case Report ◽  
Infective Endocarditis ◽  
Rare Case ◽  
Case Reports ◽  
Multidrug Resistant ◽  
The Body ◽  
Prior History ◽  
Skin Reactions ◽  
Rare Case Report ◽  
Multiple Drugs

Rationale: Linezolid (LNZ) induced Cutaneous Adverse Drug Reactions (CADRs) have rare atypical presentation. Till date, there are very few published case reports on LNZ induced CADRs among the multidrug-resistant patients suffering from Infective Endocarditis (MDR IE). Here, we present a rare case report of LNZ induced CARs in a MDR IE patient. Case report: A 24-year-old female patient was admitted to the hospital with chief complaints of fever (101°C) associated with rigors, chills, and shortness of breath (grade IV) for the past 4 days. She was diagnosed with MDR IE, having a prior history of rheumatic heart disease. She was prescribed LNZ 600mg IV BD for MDR IE, against Staphylococcus coagulase-negative. The patient experienced flares of cutaneous reactions with multiple hyper-pigmented maculopapular lesions all over the body after one week of LNZ therapy. Upon causality assessment, she was found to be suffering from LNZ induced CADRs. LNZ dose was tapered gradually and discontinued. The patient was prescribed corticosteroids along with other supportive care. Her reactions completely subsided and infection got controlled following 1 month of therapy. Conclusion: Healthcare professionals should be vigilant for rare CADRs, while monitoring the patients on LNZ therapy especially in MDR patients as they are exposed to multiple drugs. Moreover, strengthened spontaneous reporting is required for better quantification.

Sign in / Sign up

Export Citation Format

Share Document